Characterization of the renal phenotype in RMND1-related mitochondrial disease

Brian J. Shayota1,2 | Nhon T. Le3 | Nasim Bekheirnia1,3,4 | Jill A. Rosenfeld2 | Amy C. Goldstein5 | Michael Moritz6 | Dennis W. Bartholomew7 | Matthew T. Pastore7 | Fan Xia2,8 | Christine Eng2,8 | Yaping Yang2,8 | Dolores J. Lamb3,9 | Fernando Scaglia1,2,10 | Michael C. Braun1,3,4 | Mir Reza Bekheirnia1,2,3,4

1Texas Children's Hospital, Houston, TX, USA
2Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
3Baylor College of Medicine, Houston, TX, USA
4Renal Section, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
5Department of Pediatrics and Division of Child Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
6Department of Pediatrics, Division of Nephrology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
7Division of Molecular and Human Genetics, Nationwide Children's Hospital, Columbus, OH, USA
8Baylor Genetics, Baylor College of Medicine, Houston, TX, USA
9Department of Urology, Weill Cornell Medicine, New York, NY, USA
10BCM-CUHK Center of Medical Genetics, Prince of Wales Hospital, ShaTin, Hong Kong SAR

Correspondence
Mir Reza Bekheirnia, Departments of Pediatrics/Molecular and Human Genetics, Texas Children's Hospital, 1102 Bates St., Suite# 245, Houston, TX 77030, USA.
Email: bekheirn@bcm.edu

Funding information
Supported in part by K12 DK083014 Multidisciplinary K12 Urologic Research Career Development Program scholar and R01 DK078121 from the National Institute of Diabetes and Digestive and Kidney Diseases awarded to DJL. Brian J. Shayota receives funding through the NIH T32 (GM07526-41) Medical Genetics Trainee Grant.

Abstract
Background: The nuclear encoded gene RMND1 (Required for Meiotic Nuclear Division 1 homolog) has recently been linked to RMND1-related mitochondrial disease (RRMD). This autosomal recessive condition characteristically presents with an infantile-onset multisystem disease characterized by severe hypotonia, global developmental delay, failure to thrive, sensorineural hearing loss, and lactic acidosis. Renal disease, however, appears to be one of the more prominent features of RRMD, affecting patients at significantly higher numbers compared to other mitochondrial diseases. We report the clinical, histological, and molecular findings of four RRMD patients across three academic institutions with a focus on the renal manifestations.

Methods: Four patients were identified for the purpose of this study, all of whom had molecular confirmation at the time of inclusion, which included the common pathogenic variant c.713A>G (p.N238S) as well as the three rare variants: c.485delC (p.P162fs), c.533C>T (p.T178M), and c.1317 + 1G>C splice donor variant. Medical history and laboratory findings were collected from the medical records and medical providers.

Results: In this study, all four patients developed renal disease characterized as tubulopathy (3/4), renal tubular acidosis (2/4), interstitial nephritis (1/4), and/or end-stage
renal disease (4/4) necessitating renal transplantation (2/4). Histological evaluation of renal biopsy specimens revealed generalized tubular atrophy and on electron microscopy, abundant mitochondria with pleomorphism and abnormal cristae.

**Conclusion:** Our experience with RRMD demonstrates a specific pattern of renal disease manifestations and clinical course. Patients are unlikely to respond to traditional chronic kidney disease (CKD) treatments, making early diagnosis and consideration of renal transplantation paramount to the management of RRMD.

**KEYWORDS**
chronic kidney disease, Mitochondrial disease, renal transplantation, RMND1

---

1 | INTRODUCTION

Mitochondrial diseases commonly present as a complex manifestation of multisystem impairment with a predilection for metabolically active cells. This impairment typically includes varying degrees of neurologic, cardiac, ophthalmologic, and musculoskeletal dysfunction. Historically, renal disease was considered to be a relatively uncommon feature with an estimated 5%–19% of patients experiencing clinically significant renal impairment (Martin-Hernandez et al., 2005; Rotig & Munnich, 2003). **RMND1**-related mitochondrial disease (RRMD) represents a unique mitochondrial disease with a particularly high risk for clinically significant renal disease compared to other mitochondrial diseases, affecting approximately 66% of patients (Ng et al., 2016).

Separately, Garcia-Diaz et al. and Janer et al. first described clinical cases of RRMD in 2012, linking it to bi-allelic pathogenic variants in the nuclear-encoded gene **RMND1** (Required for Meiotic Nuclear Division 1 homolog, OMIM 614,917) (Garcia-Diaz et al., 2012; Janer et al., 2012). **RMND1** belongs to the evolutionary conserved sif2 family of genes that share the DUF155 domain. Additionally, it has three isoforms that contain an N-terminal mitochondrial localization signal, coiled-coil region, and C-terminal transmembrane domain (Garcia-Diaz et al., 2012). The protein product of **RMND1** is known to have an integral role in the translation of mtDNA-encoded polypeptides, which is an essential step in forming the subunits of the oxidative phosphorylation complexes. It has been hypothesized to achieve this by serving as an anchor for mitochondrial ribosomes near the site of mRNA maturation, however, the exact mechanism remains unclear (Janer et al., 2015).

Clinically, patients with RRMD typically present with an infantile-onset multisystem disease characterized by hypotonia, global developmental delay, failure to thrive, leukoencephalopathy with temporal cysts, sensorineural hearing loss, and lactic acidosis (Ng et al., 2016; Ravn, Neland, Wibrand, Duno, & Ostergaard, 2016; Ulrick et al., 2017). The spectrum of renal disease previously described in RRMD patients includes various degrees of chronic kidney disease (CKD), arterial hypertension, dysplastic/hypoplastic kidneys, and electrolyte abnormalities (Ng et al., 2016). Overall, the renal prognosis is poor with many patients progressing to end-stage renal disease (ESRD) and requiring renal replacement therapy and/or transplantation. In this report, we further define and expand the RRMD phenotype with a focus on the unique pattern of renal involvement.

2 | PATIENT PRESENTATIONS

**Patient 1:** This patient presented as a 6 year old female with history of developmental delay, intellectual disability, sensorineural hearing loss, absent speech, and short stature, as well as diminished cerebral white matter volume and leukodystrophy based on MRI imaging. A biopsy of the patient’s quadriceps muscle revealed that she had a marked reduction in complex IV activity, suggesting a mitochondrial disorder. The patient’s renal disease presented at 6 years of age, which progressed from CKD III at 7 years of age, to CKD IV at 9 years of age, and finally CKD V at 11 years of age at which point she was placed on dialysis and soon after underwent a deceased donor renal allograft. The transplantation was well tolerated and at her most recent evaluation at 14 years of age she remains clinically stable with normal renal allograft function.

**Patient 2:** This patient presented as a 2-month-old female with diarrhea and electrolyte imbalance, originally thought to be secondary to pseudohypoaldosteronism type I. At 8 months of age she was found to have moderate cerebral volume loss with delayed myelination and bilateral sensorineural hearing loss later treated with cochlear implants. Additionally, she had difficulty to control hypertension with recurrent hypokalemia, hyponatremia, and acidosis. A renal biopsy revealed chronic tubular interstitial nephritis with extensive tubular atrophy, tubular sclerosis, and a chronic inflammatory infiltrate. Higher magnification on electron microscopy revealed abnormal mitochondria, suggestive of
a mitochondrial cytopathy. Mitochondrial respiratory chain enzyme activities from a skin biopsy specimen of the patient were all within the normal range. The patient's renal disease progressed to CKD IV by 5 years of age with the recommendation to undergo renal transplantation, however, she remains stable at 7 years of age.

Patient 3: This patient presented as a 4-month-old female infant with global developmental delay, refractory epilepsy, hypotonia, microcephaly, and cortical visual impairment. MRI imaging of the brain revealed cerebral volume loss with white matter abnormalities, basal ganglia calcifications, and temporal cystic changes similar to that observed in congenital cytomegalovirus infections. At 10 years of age, her phenotype evolved to include short stature and intellectual disability. The patient's renal disease has included ESRD with secondary hypertension and renal tubular acidosis. The patient has progressed further into renal failure and has been recommended for renal transplantation at 10 years of age. This patient has been included in prior publications (Parikh et al., 2016), but new information regarding the renal phenotype has been included in this report.

Patient 4: This male patient presented with a history of reported hypoxic ischemic encephalopathy, sensorineural hearing loss, and failure to thrive. In the neonatal period, the patient had multiple cardiac arrests, pulmonary hypertension, and required extracorporeal membrane oxygenation (ECMO) for 8 days. Renal tubular acidosis developed by 6 months of age and by 18 months he rapidly progressed with hyponatremia, hyperkalemia, hyperuricemia, and hypouricosuria that was initially thought to be pseudohypoaldosteronism. A subsequent renal biopsy revealed tubular atrophy with interstitial inflammation and fibrosis. High magnification with electron microscopy found the tubular epithelial cells to have prominent mitochondria with some pleomorphism and broad, thickened cristae without crystalloid inclusions (Figure 1). By 5.5 years of age, the patient had been placed on renal replacement therapy and at 6.5 years of age received a renal transplant. The patient was most recently evaluated at 10 years of age with a well-functioning transplant. This patient has been included in prior publications (Ng et al., 2016; Parikh et al., 2016), but new information regarding the renal phenotype has been included in this report.

3 | MOLECULAR TESTING

Molecular testing for confirmation of the diagnosis was made in all four patients (Table 1). The results for the four unrelated probands include the most commonly reported pathogenic variant c.713A>G (p.N238S) as well as the three rare variants: c.485delC (p.P162fs), c.533C>T (p.T178M), and c.1317+1G>T splice donor variant. All three of these less
common variants are reported as pathogenic according to the American College of Medical Genetics guidelines (Richards et al., 2015) and have been reported in other patients with the exception of the c.533C>T (p.T178M) variant. However, a different nucleotide change at the same c.533 position that also results in a threonine to lysine substitution has been described in previous reports and labeled as a pathogenic variant as well. This variant had since been reclassified as a pathogenic variant.

**4 | DISCUSSION**

The importance of mitochondrial dysfunction in the pathophysiology of renal disease has gained momentum in recent years. This association is not surprising given that among different organs, the kidney is second only to the heart in mitochondrial count and oxygen consumption (Duann & Lin, 2017). However, not all mitochondrial diseases present with the same renal phenotype. For example, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) and a select few defects in nuclear encoded genes (CoQ2, CoQ6, PDSS2, and ADCK4) that impair coenzyme Q10 biosynthesis, classically may present with steroid-resistant nephrotic syndrome and focal segmental glomerular sclerosis (FSGS) with evidence of podocyte effacement, dysmorphic mitochondria, and arteriolar hyalinosis (Ashraf et al., 2013; Gucer et al., 2005; Seidowsky et al., 2013; Yanagihara, Oyama, Tanaka, Nakaji, & Nishimura, 2001). This finding contrasts with other mitochondrial diseases such as myoclonic epilepsy and ragged red muscle fibers (MERRF), Pearson syndrome, Kearns–Sayre syndrome, GRACILE syndrome, and some types of Leigh syndrome which more commonly develop a proximal tubular defect manifested by loss of electrolytes and presence of low molecular weight proteins in the urine (Che, Yuan, Huang, & Zhang, 2014). The mechanism by which mitochondrial defects can present with such starkly different phenotypes is not well understood at this time. While RRMD has more in common with the latter group of mitochondrial disorders, it is unique in that it presents at such an early stage of the disease and with such a high frequency.

Overall, our patients had a similar clinical presentation of RRMD compared to prior reports with global developmental delay, hypotonia, sensorineural hearing loss, failure to thrive, white matter disease, and renal disease (Table 1). Although two of the patients had been included in prior reports, additional information was obtained to better define the classification and natural history of their renal disease in this report. Notably, all four patients had some degree of renal disease, which is consistent with the prior report with a stated incidence of 66% (Ng et al., 2016). It has also been suggested

**TABLE 1** Summary of patients’ demographics, genotypes, and phenotypes

|              | Pt #1     | Pt #2     | Pt #3     | Pt #4     |
|--------------|-----------|-----------|-----------|-----------|
| Age (years)  | 13.9      | 7.2       | 7.7       | 9         |
| Sex          | F         | F         | F         | M         |
| RMND1 nucleotide change | c.485delC | c.533C > T | c.713A > G (homozygous) | c.713A > G (homozygous) |
| RMND1 amino acid change | p.P162fs | p.T178M | p.N238S (homozygous) | p.N238S (homozygous) |
| Intellectual disability | +        | −         | +         | Unk       |
| Global developmental delay | +        | −         | −         | +         |
| Motor delay   | −         | +         | +         | +         |
| Speech delay  | +         | −         | +         | Unk       |
| Microcephaly  | −         | −         | +         | −         |
| Sensorineural hearing loss | +        | +         | +         | −         |
| Cortical vision loss | −        | −         | +         | –         |
| Short stature | +         | −         | +         | +         |
| Brain anomalies | CVL, WMA | CA       | BGC, CVL, WMA | Encephalopathy |
| Cardiac anomalies | –        | –         | HTN, PFO | LVH       |
| Muscle anomalies | LA, CIVD | –        | HPO, HT/S | unk       |
| Renal dysfunction | +        | +         | +         | +         |

Note: The “+” signifies that the patient is positive and “−” negative for a given phenotype. The “unk” signifies it was not ascertained whether or not the phenotype was present at the time of evaluation.

Abbreviations: BGC, basal ganglia calcification; CA, cortical atrophy; CIVD, complex IV deficiency; CVL cerebral volume loss; HT/S, hypertonia/spasticity; HTN, hypertension; LA, lactic acidosis; LVH, left ventricular hypertrophy; PFO, patent foramen ovale; WMA, white matter abnormality
that the presence of renal disease is a good prognostic factor. However, it seems more likely that those with a more severe disease course leading to death before 12 months of age have potentially not lived long enough to develop renal disease, which does not necessarily always present clinically in the neonatal period. In this study, renal disease had been identified as early as 2 months in patient 2 and as late as 6 years in patient 1.

More specifically the clinical presentation of renal disease in our patients often included electrolyte imbalance secondary to a tubulopathy (3/4) and/or acidosis secondary to renal tubular acidosis (2/4) (Table 2). Interestingly, these clinical findings were often first suspected to be pseudohypoaldosteronism type 1 (3/4), given the similar findings of salt-wasting renal disease and acidemia. Aldosterone insensitivity had also been suspected in one other patient reported by Janer et al (Janer et al., 2015) before the diagnosis of RRMD had been made. Therefore, RRMD should always be considered in the differential for suspected pseudohypoaldosteronism type 1, especially given the differences in management and prognosis for the two disorders.

Microscopic examination of renal biopsies specimens has also been useful in guiding providers to the diagnosis of a mitochondrial disorder, although the changes generally do not appear to be specific to RRMD. Findings from this report include evidence of tubular atrophy with thyroidization, interstitial inflammation, and an over abundance of mitochondria seen on the renal biopsy specimen of patient 4. In another patient reported by Gupta et al, renal biopsy had revealed tubulointerstitial damage with immature glomeruli as well as mildly enlarged mitochondria with a fluffy granular matrix (Gupta et al., 2016). Granular swollen epithelial cells with abundant abnormally shaped mitochondria, in general, have been suggested as a strong indicator of mitochondria-related kidney disease (Finsterer & Scorza, 2017; Kobayashi, Goto, Nagata, & Yamaguchi, 2010). This appears to hold true for RRMD as well, at least among the few diagnosed patients who have undergone renal biopsy.

In this study, we have also shown that the renal disease seen in RRMD is often progressive and can lead to the need for renal replacement therapy and/or renal transplantation, as observed in all four of our patients. These results suggest that patients with RRMD tend to not respond to other traditional treatments of CKD like proper blood pressure control and a low protein diet, and thus the discussion for renal transplantation should begin early in the disease process. Fortunately, the few reported RRMD patients who have received a renal transplant have had positive outcomes. This includes patients 3 and 4, both of whom had uncomplicated renal transplants performed.

Still, there remains much to be learned about RRMD and the pathophysiological mechanism by which the renal disease occurs with such high frequency compared to other mitochondrial disorders. Although no proven effective treatment

| TABLE 2 | Summary of patients’ renal manifestations and the need for kidney transplantation |
|---------|---------------------------------------------------------------|
|                     | This report | Taylor 2014 | Janer 2015 | Ng 2016† | Gupta 2016 | Total |
| Renal dysfunction   | + + + +      | 5/6          | +          | 20/31     | +          | 31/43 |
| Pseudohypoaldosteronism-like features | Unk + + + | + | Unk | Unk | Unk | 4/4 reported |
| Chronic renal failure due to interstitial nephritis | Unk + – Unk | Unk | Unk | Unk | + | 2/3 reported |
| Tubulopathy         | Unk + – Unk  | Unk          | +          | +         | +          | 5/5 reported |
| Renal tubular acidosis | Unk – + + | 2/6          | Unk | 11/35    | Unk | 15/44 reported |
| Interstitial inflammation on renal biopsy | Unk + Unk + Unk | Unk | Unk | Unk | + | 3/3 reported |
| Abundant mitochondria in epithelial cells on renal biopsy | Unk + Unk + Unk | Unk | Unk | Unk | + | 3/3 reported |
| End-stage renal disease | + + + + | Unk          | Unk | 11/35    | +          | 16/40 reported |
| Recommended for renal transplantation | + + + + | Unk | Unk | 3/35 | unk | 7/39 reported |
| Received renal transplantation | + – – + | Unk | Unk | 3/35 | Unk | 5/39 reported |

Note: The “+” signifies that the patient is positive and “–” negative for a given phenotype. The “unk” signifies it was not ascertained whether or not the phenotype was present at the time of evaluation.
†Information regarding one patient included in this report (patient #4) and Ng et al. excluded from totals of Ng et al. to avoid counting the same patient twice.
for the renal disease seen in mitochondrial disease exists, there are encouraging findings for some specific mitochondrial conditions such as PDSS2-associated CoQ10 deficiency where administration of CoQ10 was found to have beneficial effects in affected mice (Saiki et al., 2008; Widmeier et al., 2019). Perhaps in the future new treatment modalities will be developed for other mitochondrial-related renal diseases such as RRMD to prevent and/or slow the progression of renal dysfunction and delay the need for renal replacement therapy and transplantation.

5 CONCLUSION

In summary, we have characterized the clinical and more specifically the renal phenotype observed in RRMD. Our findings suggest that the pattern of renal disease in RRMD can help differentiate it from other causes of pediatric renal disease including other mitochondrial diseases. Furthermore, our experience has shown a gradual progression of renal disease, often leading to the need for renal replacement therapy and transplantation. Therefore, regular monitoring for renal dysfunction and early consideration for renal transplantation should be a mainstay in the management of RRMD affected patients.

CONFLICTS OF INTEREST

The authors declare that they have no conflict of interest.

ORCID

Brian J. Shayota https://orcid.org/0000-0003-4657-6454

REFERENCES

Ashraf, S., Gee, H. Y., Woerner, S., Xie, L. X., Vega-Warner, V., Lovric, S., … Hildebrandt, F. (2013). ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest, 123(12), 5179–5189. https://doi.org/10.1172/JCI69000

Che, R., Yuan, Y., Huang, S., & Zhang, A. (2014). Mitochondrial dysfunction in the pathophysiology of renal diseases. American Journal of Physiology. Renal Physiology, 306(4), F367–378. https://doi.org/10.1152/ajprenal.00571.2013

Duann, P., & Lin, P. H. (2017). Mitochondria damage and kidney disease. Advances in Experimental Medicine and Biology, 982, 529–551. https://doi.org/10.1007/978-3-319-55330-6_27

Finsterer, J., & Scorza, F. A. (2017). Renal manifestations of primary mitochondrial disorders. Biomed Rep, 6(5), 487–494. https://doi.org/10.3892/br.2017.892

García-Díaz, B., Barros, M. H., Sanna-Cherchi, S., Emmanuele, V., Akman, H. O., Ferreiro-Barros, C. C., … Quinzi, C. M. (2012). Infantile encephaloneuromyopathy and defective mitochondrial translation are due to a homozygous RMND1 mutation. American Journal of Human Genetics, 91(4), 729–736. https://doi.org/10.1016/j.ajhg.2012.08.019

Güçer, Ş., Talim, B., Aşan, E., Korkusuz, P., Özen, S., Ünal, Ş., … Çağlar, M. (2005). Focal segmental glomerulosclerosis associated with mitochondrial cytopathy: Report of two cases with special emphasis on podocytes. Pediatric and Developmental Pathology, 8(6), 710–717. https://doi.org/10.1007/s10024-005-0058-z

Gupta, A., Colmenero, I., Ragge, N. K., Blakely, E. L., He, L., McFarland, R., … Milford, D. V. (2016). Compound heterozygous RMND1 gene variants associated with chronic kidney disease, dilated cardiomyopathy and neurological involvement: A case report. BMC Research Notes, 9, 325. https://doi.org/10.1186/s13104-016-2131-2

Janer, A., Antonicka, H., Lalonde, E., Nishimura, T., Sasarman, F., Brown, G. K., … Shoubridge, E. A. (2012). An RMND1 Mutation causes encephalopathy associated with multiple oxidative phosphorylation complex deficiencies and a mitochondrial translation defect. American Journal of Human Genetics, 91(4), 737–743. https://doi.org/10.1016/j.ajhg.2012.08.020

Janer, A., van Karnebeek, C. D. M., Sasarman, F., Antonicka, H., Al Ghamdi, M., Shyr, C., … Shoubridge, E. A. (2015). RMND1 deficiency associated with neonatal lactic acidosis, infantile onset renal failure, deafness, and multorgan involvement. European Journal of Human Genetics, 23(10), 1301–1307. https://doi.org/10.1038/ejhg.2014.293

Kobayashi, A., Goto, Y., Nagata, M., & Yamaguchi, Y. (2010). Granular swollen epithelial cells: A histologic and diagnostic marker for mitochondrial nephropathy. American Journal of Surgical Pathology, 34(2), 262–270. https://doi.org/10.1097/PAS.0b013e3181c4ed3

Martin-Hernández, E., García-Silva, M. T., Vara, J., Campos, Y., Cabello, A., Muley, R., … Arenas, J. (2005). Renal pathology in children with mitochondrial diseases. Pediatric Nephrology(Berlin, Germany), 20(9), 1299–1305. https://doi.org/10.1007/s00467-005-1948-z

Ng, Y. S., Alston, C. L., Diodato, D., Morris, A. A., Ulrick, N., Knoch, S., … McFarland, R. (2016). The clinical, biochemical and genetic features associated with RMND1-related mitochondrial disease. Journal of Medical Genetics, 53(11), 768–775. https://doi.org/10.1136/jmedgenet-2016-103910

Parikh, S., Karaa, A., Goldstein, A., Ng, Y. S., Gorman, G., Feigenbaum, A., … Scaglia, F. (2016). Solid organ transplantation in primary mitochondrial disease: Proceed with caution. Molecular Genetics and Metabolism, 118(3), 178–184. https://doi.org/10.1016/j.ymgme.2016.04.009

Ravn, K., Neland, M., Wibrand, F., Duno, M., & Ostergaard, E. (2016). Hearing impairment and renal failure associated with RMND1 mutations. American Journal of Medical Genetics. Part A, 170A(1), 142–147. https://doi.org/10.1002/ajmg.a.37399

Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., … Rehm, H. L. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine, 17(5), 405–424. https://doi.org/10.1038/gim.2015.30

Rotig, A., & Munnich, A. (2003). Genetic features of mitochondrial respiratory chain disorders. Journal of the American Society of
Nephrology, 14(12), 2995–3007. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/14638899. https://doi.org/10.1097/01.ASN.0000095481.24091.C9

Saiki, R., Lunceford, A. L., Shi, Y., Marbois, B., King, R., Pachuski, J., … Clarke, C. F. (2008). Coenzyme Q10 supplementation rescues renal disease in Pdds2kd/kd mice with mutations in prenyl diphosphate synthase subunit 2. American Journal of Physiology. Renal Physiology, 295(5), F1535–1544. https://doi.org/10.1152/ajprenal.90445.2008

Seidowsky, A., Hoffmann, M., Glowacki, F., Dhaenens, C. M., Devaux, J. P., de Sainte Foy, C. L., … Buob, D. (2013). Renal involvement in MELAS syndrome - a series of 5 cases and review of the literature. Clinical Nephrology, 80(6), 456–463. https://doi.org/10.5414/CN107063

Ulrick, N., Goldstein, A., Simons, C., Taft, R. J., Helman, G., Pizzino, A., … Vanderver, A. (2017). RMND1-related leukencephalopathy with temporal lobe cysts and hearing loss—another mendelian mimic of Congenital cytomegalovirus infection. Pediatric Neurology, 66, 59–62. https://doi.org/10.1016/j.pediatrneurol.2016.09.003

Widmeier, E., Airik, M., Hugo, H., Schapiro, D., Wedel, J., Ghosh, C. C., … Hildebrandt, F. (2019). Treatment with 2,4-dihydroxybenzoic acid prevents FSGS progression and renal fibrosis in podocyte-specific Coq6 knockout mice. Journal of the American Society of Nephrology, 30(3), 393–405. https://doi.org/10.1681/ASN.2018060625

Yanagihara, C., Oyama, A., Tanaka, M., Nakaji, K., & Nishimura, Y. (2001). An autopsy case of mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome with chronic renal failure. Internal Medicine, 40(7), 662–665. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11506313. https://doi.org/10.2169/internalmedicine.40.662

How to cite this article: Shayota BJ, Le NT, Bekheirnia N, et al. Characterization of the renal phenotype in RMND1-related mitochondrial disease. Mol Genet Genomic Med. 2019;7:e973. https://doi.org/10.1002/mgg3.973